Cargando…

New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties

BACKGROUND: Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the treatment of ADHD. Its clinical and safety profi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Chungping, Garcia-Olivares, Jennie, Candler, Shawn, Schwabe, Stefan, Maletic, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473988/ https://www.ncbi.nlm.nih.gov/pubmed/32943948 http://dx.doi.org/10.2147/JEP.S256586

Ejemplares similares

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
por: Findling, Robert L., et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults
por: Wang, Zhao, et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Correction to: Viloxazine: Pediatric First Approval
por: Lamb, Yvette N.
Publicado: (2023)

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
por: Johnson, Janet K., et al.
Publicado: (2019)

Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice
por: Singh, Paramdeep, et al.
Publicado: (2015)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

Selective Serotonin–norepinephrine Reuptake Inhibitors-induced Takotsubo Cardiomyopathy
por: Vasudev, Rahul, et al.
Publicado: (2016)

New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations
por: Fanelli, David, et al.
Publicado: (2021)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2007)

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome
Publicado: (2016)

Serotonin-norepinephrine reuptake inhibitors may exacerbate stiff-person syndrome
por: Benavides, David R., et al.
Publicado: (2016)

Design and Synthesis of Arylamidine Derivatives as Serotonin/Norepinephrine Dual Reuptake Inhibitors
por: Wen, Hui, et al.
Publicado: (2019)

Treatment of Alzheimer’s Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions
por: Ashford, John Wesson
Publicado: (2019)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Structural Requirements for Modulating 4-Benzylpiperidine Carboxamides from Serotonin/Norepinephrine Reuptake Inhibitors to Triple Reuptake Inhibitors
por: Paudel, Suresh, et al.
Publicado: (2021)

NOREPINEPHRINE AND SEROTONIN METABOLISM AND CLINICAL RESPONSE TO COMBINED IMIPRAMINE AND AMITRIPTYLINE THERAPY IN DEPRESSION
por: Palaniappun, V., et al.
Publicado: (1991)

Norepinephrine potentiates and serotonin depresses visual cortical responses by transforming eligibility traces
por: Hong, Su Z., et al.
Publicado: (2022)

Mixed lymphocytic and collagenous inflammation of the entire gastrointestinal tract under therapy with serotonin and norepinephrine reuptake inhibitors
por: Varelas, Ana I., et al.
Publicado: (2022)

The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review
por: Maletic, Vladimir, et al.
Publicado: (2017)

Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
por: Martino, Matteo, et al.
Publicado: (2012)

Serotonin and Norepinephrine Transporter Occupancy of Tramadol in Nonhuman Primate Using Positron Emission Tomography
por: Arakawa, Ryosuke, et al.
Publicado: (2018)

Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
por: Qin, Xuan, et al.
Publicado: (2022)

Delayed Presentation of Posterior Reversible Encephalopathy Syndrome in the Setting of Serotonin-Norepinephrine Reuptake Inhibitors
por: Bhutada, Abhishek S, et al.
Publicado: (2022)

Monoamine Oxidase A Contributes to Serotonin—But Not Norepinephrine-Dependent Damage of Rat Ventricular Myocytes
por: Knittel, Jonas, et al.
Publicado: (2023)

Mechanism of triazolo-benzodiazepine and benzodiazepine action in anxiety and depression: Behavioral studies with concomitant in vivo CA(1) hippocampal norepinephrine and serotonin release detection in the behaving animal
por: Broderick, Patricia A., et al.
Publicado: (1998)

Enriched environmental exposure reduces the onset of action of the serotonin norepinephrin reuptake inhibitor venlafaxine through its effect on parvalbumin interneurons plasticity in mice
por: Coutens, Basile, et al.
Publicado: (2023)

Serotonin, Dopamine and Noradrenaline Adjust Actions of Myelinated Afferents via Modulation of Presynaptic Inhibition in the Mouse Spinal Cord
por: García-Ramírez, David L., et al.
Publicado: (2014)

Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials
por: Singh, Alok, et al.
Publicado: (2022)

Inhibition of the Serotonin Transporter Is Altered by Metabolites of Selective Serotonin and Norepinephrine Reuptake Inhibitors and Represents a Caution to Acute or Chronic Treatment Paradigms
por: Krout, Danielle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_761300lq18qm0r8a5q2ss15qtv